BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Pharma Journalist - ECPv6.16.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Pharma Journalist
X-ORIGINAL-URL:https://www.pharmajournalist.com
X-WR-CALDESC:Events for Pharma Journalist
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:Asia/Kolkata
BEGIN:STANDARD
TZOFFSETFROM:+0530
TZOFFSETTO:+0530
TZNAME:IST
DTSTART:20190101T000000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201110
DTEND;VALUE=DATE:20201113
DTSTAMP:20260515T140654
CREATED:20200722T114844Z
LAST-MODIFIED:20200722T114844Z
UID:26443-1604966400-1605225599@www.pharmajournalist.com
SUMMARY:3rd Annual Lab Asset & Facility Management in Pharma 2020
DESCRIPTION:The 3rd Lab Asset & Facility Management in Pharma will return to Boston this Winter as your ONLY industry led meeting focusing on R&D asset and FM\, enabling you to regain control of your assets\, optimize your space and benchmark best practices to stay ahead of the curve. \n \nThrough strategic planning and rolling out digital tracking\, Lab Asset\, Operations and FM Directors are beginning to regain control of their inventory\, asset value and optimize facility footprint to: \n\nReduce unnecessary downtime and ensure reliable business operations\nStrengthen relationships and drive innovative partnership models with OEMs\nMaximize asset lifecycle and value – and make informed financial decisions during purchasing\, renewing\, reselling and auctioning\nOptimize lab and working space\, implementing the ethos of shared economy within the R&D scientific community\nEnhance capital efficiency to re-invest in drug development programs\nAnticipate expansion from a lab and equipment perspective
URL:https://www.pharmajournalist.com/event/3rd-annual-lab-asset-facility-management-in-pharma-2020/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201110
DTEND;VALUE=DATE:20201113
DTSTAMP:20260515T140654
CREATED:20200727T160850Z
LAST-MODIFIED:20200727T160850Z
UID:26517-1604966400-1605225599@www.pharmajournalist.com
SUMMARY:Digital Neuropsychiatric Drug Development Summit
DESCRIPTION:The 3rd Annual Neuropsychiatric Drug Development Summit will return in November 2020 as an interactive\, virtual meeting. This definitive industry meeting is focused on helping you develop the next generation of more clinically effective therapeutics. \n \nWith an emphasis on depressive disorders\, schizophrenia\, addiction and PTSD\, this timely meeting provides a much-needed platform for industry and academic thought leaders to: \n\nDive into novel therapeutic approaches for PTSD with Aptinyx\, Bionomics\, Tonix & MAPS\nUncover the emergence of the next generation of anti-psychotics with Karuna Therapeutics\, NeuroRx & Intra-cellular Therapeutics\nExplore industry approaches for innovative trial design and new methods to modelling the placebo response with Novartis\, Otsuka & Yale University\nHear how pioneering biotechs are spearheading drug development for substance use disorders with Opiant Pharmaceuticals & the NIDA\nLearn how to advance neurophysiology and cognition translational biomarkers and be part of the drive towards precision medicine with Takeda & UT Southwestern\n\nUniting 60+ drug developers from all corners of the world\, Neuropsychiatric Drug Development is your opportunity to discuss in depth how to push forward the frontiers of neuropsychiatric drug development to develop the next generation of more clinically effective therapeutics. \nTo know more about Digital Neuropsychiatric Drug Development Summit please click here.
URL:https://www.pharmajournalist.com/event/digital-neuropsychiatric-drug-development-summit/
LOCATION:Virtual Event
ORGANIZER;CN="Hanson Wade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201110
DTEND;VALUE=DATE:20201114
DTSTAMP:20260515T140654
CREATED:20200818T085642Z
LAST-MODIFIED:20200818T090545Z
UID:26793-1604966400-1605311999@www.pharmajournalist.com
SUMMARY:TIDES Europe: Oligonucleotide & Peptide Therapeutics 2020
DESCRIPTION:Europe’s #1 forum for oligonucleotide\, peptide\, CRISPR and mRNA therapeutic leaders to discuss scientific strategies and accelerate products to market\, while also creating new successful partnerships. This year’s virtual agenda features 5 scientific tracks covering in-depth development strategies\, trends and technologies across the entire oligonucleotide and peptide spectrum; as well as a partnering track that will keep you ahead of your competition\, and work towards collaborations.
URL:https://www.pharmajournalist.com/event/tides-europe-oligonucleotide-peptide-therapeutics-2020/
LOCATION:100% Virtual
ORGANIZER;CN="Informa Connect":MAILTO:Allison.MacDonald@informa.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201110
DTEND;VALUE=DATE:20201111
DTSTAMP:20260515T140654
CREATED:20200821T150457Z
LAST-MODIFIED:20200821T150457Z
UID:26819-1604966400-1605052799@www.pharmajournalist.com
SUMMARY:2nd Annual Biomarkers for Rare Non-Oncological Disorders
DESCRIPTION:The Digital 2nd Annual Biomarkers for Rare Non-Oncological Diseases Summit will unite biopharma\, diagnostic and healthcare teams to advance the application of precision medicine in rare diseases beyond oncology. \nThis event is completely free for Drug Developers\, Researchers and Academics. To register your complimentary pass\, simply follow this link: www.nononcologyraredisease-summit.com/take-part/register/ \nTackling critical challenges from early research through to late-stage market access\, this meeting is the must-attend summit for industry-led insights in delivering novel treatments for patients in need. \n How Will it Help You Deliver Predictive Markers & Effective Drug-Dx Products? \n Drawing on a multitude of disease areas spanning neurology\, cardiology\, metabolic\, renal\, inflammatory and more\, the meeting combines a range of perspectives and experiences for unparalleled learning opportunities. \nWith 2 days of in-depth case studies\, interactive panel discussions\, dedicated Q+A time and valuable networking opportunities\, you can walk away with improved end-to-end strategies from early biomarker validation to effective clinical trials and enabling successful regulatory\, payer and commercial discussions. \nTake a look at the full event guide to see all case studies\, pre-conference workshop details and the full expert speaker faculty!
URL:https://www.pharmajournalist.com/event/2nd-annual-biomarkers-for-rare-non-oncological-disorders/
LOCATION:Digital Event
ORGANIZER;CN="Hansonwade":MAILTO:info@hansonwade.com
END:VEVENT
BEGIN:VEVENT
DTSTART;VALUE=DATE:20201110
DTEND;VALUE=DATE:20201112
DTSTAMP:20260515T140654
CREATED:20201109T092141Z
LAST-MODIFIED:20201109T092440Z
UID:27850-1604966400-1605139199@www.pharmajournalist.com
SUMMARY:Microbiome Connect: Skin 2020
DESCRIPTION:2019 proved to be a pivotal year for the skin microbiome\, as personal care giants Unilever launched their Dove range of ‘microbiome-friendly’ skincare products. Clearly\, the biggest players in beauty and personal care have recognised the potential commercial value of skin microbiome-based consumer product claims and formulations. \n \nMoving forward into 2021\, the market will continue to see more and more products launched with microbiome claims backed through next-generation sequencing techniques. Including ingestible beauty products that influence the gut-skin axis\, to truly personalised skincare solutions and mass market formulations – there’s a huge commercial opportunity to commercialise skin microbiome research into consumer care products. \nSo\, what’s different at Microbiome Connect: Skin EU Virtual? \nSix new topics to explore: \n\nThe skin-gut axis and the development of ingestible beauty products.\nPersonalisation of skin-microbiome products and formulation considerations.\nDefining skin-microbiome industry terminology and developing scientifically backed claims that resonate with consumers.\nNext generation sequencing techniques and their application in claims development.\nNew data demonstrating the role of the microbiome in common skin conditions including acne\, eczema and dandruff.\nThe vaginal and oral microbiomes and the mass market product development opportunities to treat gingivitis/periodontitis and sexually transmitted infections.\n\nAll tickets to tune into this event are 2FOR1 – simply quote this when booking online!
URL:https://www.pharmajournalist.com/event/microbiome-connect-skin-2020/
LOCATION:Virtual Event
ORGANIZER;CN="Kisaco Research":MAILTO:events@kisacoresearch.com
END:VEVENT
END:VCALENDAR